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Objectives: Breast disease remains a major public health issue worldwide. It is the most 
common cancer among Nigerian women. Fine needle aspiration cytology (FNAC) is an 
important preoperative assessment tool along with clinical and mammography examination in 
both screen detected and symptomatic breast disease. This study provide opportunity to 
determining the accuracy of FNAC and factors affecting false negative rate in Obafemi 
Awolowo University Teaching Hospital complex, Ile-Ife, Osun state Nigeria 
Method: All patients seen in the breast clinic with lump were sent to the pathology department 
for FNAC from January 1997 to December 2004.The sociodemographic data; cytology result, 
final histology result and the clinical staging for breast cancer were analyzed.      
Results: Eight hundred and sixty-four patients had FNAC during the studied period, however 
only 632 cases had available final histological report.  Of these, 20 (3.2%) were male while 612 
(96.8%) were female, the age ranged from 15 years to 99 years, median of 36.50. We found 
that absolute sensitivity for malignancy to be 70.8%.  The false negative rate  was 14.9%, while 
the false positive rate was 1.8%.  The suspicious rate was 9.8% while the inadequate rate was 
5.4%. 
Conclusion: FNAC remains the least invasive, the most rapid and the most cost effective 
method to confirm clinical and radiological suspicion of malignancy, however, the test has high 
false negative rate. We recommend that consultation between pathologists and the clinicians 
should be facilitated and encouraged to reduce the high false negative. Also, multi-disciplinary 




The interest in breast diseases stems from the 
concern aroused in patients and clinician 
following the diagnosis of breast cancer1. 
While the overall mortality due to breast 
cancer has been on the decline in the 
developed world due to early detection and 
treatment2,3, the reverse is the case in Nigeria 
and most of the developing countries4-7. 
Indeed, breast cancer is the most common 
female cancer in Nigeria and patients present 
late with the very advanced stages of the 
disease8.   
 
Fine needle aspiration cytology (FNAC) has 
been used as a preoperative assessment tool 
together with clinical and mammographic 
examination in both screen detected and 
symptomatic breast disease9. It is relatively 
less invasive, rapid and cost effective in 
confirming a clinical or radiological suspicion 
of malignancy10. It has been reported to be a 
very sensitive and specific test11, 12, however, 
it is examiner dependent in that predictive 
results depend on who performs the 
aspiration, whether a clinician or a 
cytopathologist12,13. This article is a 
presentation of how FNAC has been useful in 
diagnosing breast lumps at Obafemi Awolowo 
University Teaching Hospital complex 
[OAUTHC], Ile-Ife, Osun state Nigeria 
  
Patients and Methods 
 
Consecutive patients complaining of breast 
lumps seen between January 1997 and 
December 2004 at the surgical outpatient 
clinic of OAUTHC Ile Ife, Osun state, Nigeria 
and who had FNAC done were recruited for 
studying. They also included patients who had 
severe mastalgia and had FNAC under 
ultrasound guidance. The hospital is a tertiary 
referral center which serves the health needs 
of the semi-urban and rural communities of 
Osun, Ekiti, and Ondo states in southwestern 
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Nigeria. All patients were duly informed and 
consented. The procedure was carried out, 
according to standard guidelines as described 
by the National Health Service (NHS) Breast 
Screening Programme14, in the morbid 
anatomy department by resident and 
consultant pathologist. Following an aspirate, 
thin smears on three or four duly labeled 
slides were prepared and stained using 
Haematoxylin and Eosin [H &E] stains. The 
samples were reported based on NHS Breast 
Screening Programme14 protocol having the 
C1 defined as inadequate or unsatisfactory 
smear; C2-benign cells present; C3-mild 
atypia within some cells but probably benign; 
C4-suspicious of malignancy; C5-malignant 
cells present. Those patients suspected on 
clinical grounds to have mitotic lesions and 
those in whom cytopathology results were 
inconclusive also had incisional biopsies.  
The histopathological findings of the patients 
who had excisional biopsy or incisional 
biopsy or mastectomy were compared with 
their cytopathology reports. The final 
histological diagnosis was based on 
examination of the formalin fixed, paraffin 
embedded and Haematoxylin and Eosin 
stained sections of the biopsy.  The definitions 
employed were those used by the NHS breast 
screening Programme and these are 
reproduced in Table 115, 16.  Staging was done 
using the Manchester classification [UICC 
1960]. The data was analyzed using SPSS 
11.0 statistical software package.   
Results 
There were 864 patients with breast lumps 
who had FNAC during the study period but 
only 632 of them had corresponding 
histopathological report for comparison.  Of 
these, 20 (3.2%) were males while 612 
(96.8%) were females. Their ages ranged from 
15 to 99 years with a mean age of 39.3 
(Standard Deviation=16.2 and median of 36.5 
years). The overall audit results are 
summarized in Table 2. 
 
Table 1.Definition of sensitivity and specificity used in the cytology quality assurance audit routine 
Performance measures Definition 
Absolute sensitivity The number of C5 [cytologically diagnosed carcinomas) diagnosed as such 
expressed as a percentage of the total number of histologically confirmed 
carcinomas including inadequate samples 
Complete sensitivity The number of C2-5 (atypia/suspicious/carcinomas) expressed as a percentage 
of the total number of carcinomas 
Specificity The number of correctly identified benign lesions expressed as a percentage of 
the total number of benign lesions sampled 
PPV of C5  The number of correctly identified carcinomas expressed as a percentage of C5 
PPV of C4 (suspicious) The number of carcinomas identified as C4 (suspicious) expressed as a 
percentage of the total number of C4 
PPV of C3 (atypia, 
uncertain significance) 
The number of carcinomas identified as C3 (uncertain) expressed as a 
percentage of the total number of C3. 
False-negative rate Cases found to be carcinomas that were originally classified as C2 expressed as 
a percentage of the total number of carcinomas 
False-positive rate Cases found to be benign that were originally classified as C5 expressed as a 
percentage of the total number of carcinomas 
Suspicious rate (C3-4) Number of C3-4 expressed as a percentage of the total number of  cases 
Inadequate rate Number of C1 expressed as a percentage of the total number of cases 
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Table 2. Summary of Audit Findings 
 C1 C2 C3 C4 C5 
Total Number 
Percentage of total 
No follow-up histology 
Benign histology 




























Table 3. Final Histological Diagnosis 
Cases Frequency Percentage 
Breast Cancer 
Fibroadenoma 

























Table 4. Measures of Performance of Cytological diagnosis 
Measure of Perormance Results 
Absolute sensitivity for malignancy C5 
Complete sensitivity 
Specificity 
Number of false positive cases 
Number of false Negative cases 
False positive rate for C5 
False negative rate for C5 
PPV1 of C5 for malignancy 
PPV of C4 for Malignancy 
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Table 5. Distribution of the clinical staging and cytological Diagnosis 
Clinical 
staging 




































Likelihood Ratio: 114.545 df 12 p = 000 
 
Table 6.  Age Distribution versus False Negative Rate 
  










Total 582 50 
Likelihood Ratio: 6.634  df 2  P = 0.036 
 
The various final histological diagnoses are 
presented in Table 3. The most common 
histological diagnosis in this series was breast 
cancer in 336 (53.2%) of cases.  This was 
followed by fibroadenoma in 150 (23.7%) and 
fibrocystic disease of the breast in 92 (14.5%). 
Using the final histological diagnoses as the 
standard, it would be noted that absolute 
sensitivity for malignancy was 70.8% (Table 
4).  The false negative rate for C5 
(cytologically malignant smears) was 14.9%, 
while the false positive rate for C5 was 1.8%.  
The suspicious rate was 9.8% while the 
inadequate rate was 5.4%. Of the 48 with C4 
(suspicious smears), 42(87.5%) were found to 
be malignant on histological examination.  
Among the C4 lesions confirmed to be benign 
on histology, there were 2 (4.2%) cases of 
fibrocystic disease, 4 (8.3%) cases of 
fibroadenoma. Similarly, of the 14 with C3 
(atypia smears), 6(42.8%) were breast cancer, 
6(42.8%) fibrocystic disease and 2(14.4%) 
fibroadenoma. Table 5 compares the 
cytological diagnoses of the malignant cases 
with the clinical staging (Manchester staging). 
As expected, it was found that the higher the 
staging, the higher the chances of making the 
cytological diagnosis of malignant condition. 
The age distribution of cases of false 
negatives was shown in (Table 6). It appeared 
that patients within the age 20 – 50 years with 
malignant lesion were more likely to be 
missed by cytology than other age brackets 




In this study, we found the absolute sensitivity 
for malignancy to be 70.8%, complete 
sensitivity of 79.2% and specificity of 88.2%. 
Similarly, the false negative rate for C5 was 
14.9%, the false positive rate for C5 was 1.8% 
and the inadequate rate was 5.4%. These 
figures are comparable to data from some 
studies done in other centres11-12, 17-19.  
However, the false negative rate is relatively 
high with marginally high false positive rate. 
The implication of the high false negative rate 
was that a few patients that presented with 
early breast cancer were missed. These 
patients will likely present with features of 
advanced disease on a latter date. Most 
patients with breast cancer in this environment 
present with the late stage of the disease20. 
Late presentation in this environment has been 
attributed to prolonged denial and poverty. 
Fear of mastectomy is another major problem 
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deterring early presentation of women with 
breast cancer21,22. This, occasionally, may lead 
to seeking alternative modes of therapy such 
as herbal preparations and visiting spiritual 
houses in an effort to avoid the disfigurement 
of mastectomy. In a little way, the high false 
negative rate of this test may also contribute to 
this phenomenon. This has been related to 
sampling error and also the difficulty in 
performing required standard staining 
procedures such as Papanicolaou and Giemsa 
methods, in our laboratory. Inadequate 
funding of the laboratories in the country may 
account for the unavailability of these stains. 
Inappropriate staining will ultimately lead to 
interpretation error by the cytopathologist. 
Moreover, the interpretation error is found to 
be higher the some histological types of 
cancer especially lobular and tubular cancer, 
in patient below age 40 years, tumours of less 
than 2cm in diameter and early breast 
cancer19, 23.    
 
Another reason for the high false negative rate 
in our study could be due to sampling error. 
This can be minimized by proper localization 
and aspiration technique23. Proper localization 
can be aided using ultrasound, stereotatic x-
ray guided technique and the use of perforated 
or fenestrated plate24-26. Another disturbing 
finding in this series is the marginally high 
false positive rate. This portends unnecessary 
extensive surgery in some of our patients 
which is associated with physical and 
psychological morbidity. 
          
Sequel to the shortcoming associated with 
FNAC, there has been a reduction in the use 
of this procedure for diagnosing breast cancer 
in developed countries .The use of FNAC is 
now limited to providing accurate and rapid 
diagnoses for women and men with benign 
changes and metastatic diseases27. Core 
biopsy [CB] has largely superseded FNACB 
in most developed countries. The specificity 
and the sensitivity of CB are much higher with 
bearable false negative and false positive 
rates28. Several innovations have gone into the 
use of CB so as to make the procedure simpler 
and less often associated complications29. 
Most of the innovative biopsy forceps are not 
available in a developing country like ours. 
Moreover, histopathology results take up to 
seven to fourteen days before they are 
available. In our environment, FNACB still 
remains the cheapest and fastest alternatives 
for first line patient management. The cost of 
FNAC is about N750.00 [$5] as compared to 
N7, 000 to N10, 000[$48-$68] for surgical 
tissue biopsy. This should have a greater 
impact in developing country with limited 
resources and poor health care insurance 
coverage.   
 
Diagnostic accuracy of the report is highly 
dependent on the training and experience of 
the cytopathologist30.  It is advised that 
caution should be employed when dealing 
with suspicious lesions at an early stage and in 
younger individuals. To improve the 
diagnostic accuracy of FNAC, feedback 
information of follow up and histology from 
all cases must be made available as soon as 
possible.  Consultation between pathologists 
and clinicians should be facilitated and 
encouraged. Also, multi-disciplinary audit of 
difficult case should be part of the work 
routine.  Moreover, the use of autocytofix and 
liquid based cytology can help to increase 
smear cellularity, reduce erythrocyte load and 
air drying artefact and eventual improvement 




In conclusion, FNAC remains the least 
invasive, the most rapid and the most cost 
effective method to confirm clinical and 
radiological suspicion of malignancy, 
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